<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127114</url>
  </required_header>
  <id_info>
    <org_study_id>04033101</org_study_id>
    <nct_id>NCT00127114</nct_id>
  </id_info>
  <brief_title>Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)</brief_title>
  <official_title>Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to test whether or not the medication amantadine is
      effective in reducing behavioral disturbances in patients with frontotemporal dementia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Behavioral disturbances are a major cause of morbidity in frontotemporal dementia (FTD), yet
      little is known about the effectiveness of medications to treat these disturbances.
      Preliminary data suggests that the dopaminergic agent amantadine may reduce these
      disturbances. This 6-week, prospective, randomized, placebo-controlled trial will compare
      amantadine to placebo to assess its effectiveness in reducing behavioral symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No funding and exclusion criteria were to stringent.
  </why_stopped>
  <start_date type="Actual">September 2005</start_date>
  <completion_date type="Actual">July 26, 2007</completion_date>
  <primary_completion_date type="Actual">July 26, 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frontal Behavioral Inventory, disinhibition subscale</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frontal Behavior Inventory, total score</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric Inventory</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apathy Evaluation Scale</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive measures - Mini Mental State Exam (MMSE), Trails Making Test A&amp;B (Trails A&amp;B), Verbal fluency, and Stroop test</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) measures</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zarit Burden Interview</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <arm_group_label>Amantadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Frontotemporal dementia meeting diagnostic criteria of the Report of the Work Group on
             Frontotemporal Dementia and Pick's Disease (McKhann et al, 2001). Diagnosis will be
             established by clinical interview by a geriatric psychiatrist or neuropsychiatrist,
             experienced with the diagnosis of FTD. Patients with the language presentation of FTD
             will be enrolled if their behavioral disturbance meets the inclusion criteria. Use of
             these diagnostic criteria would allow for enrollment of patients who in a clinical
             setting carry the diagnosis of: semantic dementia, primary progressive aphasia,
             cortical-basal degeneration, progressive supranuclear palsy, (amyotrophic lateral
             sclerosis (ALS) with dementia, and Pick's disease, as all of these diagnoses are now
             classified under the rubric of FTD.

          -  Frontal Behavioral Inventory (FBI) disinhibition subscale score of &gt;16 (Kertesz et
             al,1997; Kertesz et al 2000). Explanation of this subscale is found under outcome
             measures.

          -  Men, women and minority groups will be included, ages 40-90 years old.

          -  Judged by the attending psychiatrist to be in sufficiently good health so as to be
             treated using the study protocol in usual outpatient care circumstances.

          -  Patient, caregivers and or legal representatives provide informed consent for
             participation in the study, using standard Johns Hopkins Division of Geriatric
             Psychiatry and Neuropsychiatry procedures.

          -  Caregiver is available who spends at least 10 hours per week with the patient and is
             able and willing to accompany the patient in the course of the study and to provide
             collateral information.

        Exclusion Criteria:

          -  Presence of a brain disease that might otherwise fully explain the presence of
             dementia or behavior disturbance, such as stroke, Parkinson's disease, traumatic brain
             injury, multiple sclerosis, and the like.

          -  Treatment with amantadine is contraindicated in the opinion of the study attending
             psychiatrist. Examples of this would be patients with advanced heart, liver or kidney
             disease or a seizure disorder. Creatinine clearance &gt;50mL/min will be required,
             calculated using the Cockcroft-Gault equation.

          -  Failure of treatment with amantadine for behavior disturbance of FTD in the past.

          -  Treatment with a medication that would prohibit the safe concurrent use of amantadine.

          -  Ongoing regular alcohol use and an unwillingness to stop drinking alcohol during the
             study period.

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David M Blass, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine, Outpatient General Clinical Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alzgmd.org</url>
    <description>Alzheimer Association website</description>
  </link>
  <reference>
    <citation>Drayton SJ, Davies K, Steinberg M, Leroi I, Rosenblatt A, Lyketsos CG. Amantadine for executive dysfunction syndrome in patients with dementia. Psychosomatics. 2004 May-Jun;45(3):205-9.</citation>
    <PMID>15123844</PMID>
  </reference>
  <reference>
    <citation>O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003 Jul;60(7):996-8.</citation>
    <PMID>12873857</PMID>
  </reference>
  <reference>
    <citation>Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002 Sep 10;59(5):694-9.</citation>
    <PMID>12221159</PMID>
  </reference>
  <reference>
    <citation>Van Reekum R, Bayley M, Garner S, Burke IM, Fawcett S, Hart A, Thompson W. N of 1 study: amantadine for the amotivational syndrome in a patient with traumatic brain injury. Brain Inj. 1995 Jan;9(1):49-53.</citation>
    <PMID>7874096</PMID>
  </reference>
  <reference>
    <citation>Imamura T, Takanashi M, Hattori N, Fujimori M, Yamashita H, Ishii K, Yamadori A. Bromocriptine treatment for perseveration in demented patients. Alzheimer Dis Assoc Disord. 1998 Jun;12(2):109-13.</citation>
    <PMID>9651140</PMID>
  </reference>
  <reference>
    <citation>Kertesz A, Davidson W, McCabe P, Munoz D. Behavioral quantitation is more sensitive than cognitive testing in frontotemporal dementia. Alzheimer Dis Assoc Disord. 2003 Oct-Dec;17(4):223-9.</citation>
    <PMID>14657786</PMID>
  </reference>
  <reference>
    <citation>McDowell S, Whyte J, D'Esposito M. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. Brain. 1998 Jun;121 ( Pt 6):1155-64.</citation>
    <PMID>9648550</PMID>
  </reference>
  <reference>
    <citation>Sj√∂gren M, Minthon L, Passant U, Blennow K, Wallin A. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Neurobiol Aging. 1998 Sep-Oct;19(5):379-84.</citation>
    <PMID>9880039</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2005</study_first_submitted>
  <study_first_submitted_qc>August 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2005</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Behavioral disturbance</keyword>
  <keyword>Frontotemporal dementia</keyword>
  <keyword>Dementia</keyword>
  <keyword>Amantadine</keyword>
  <keyword>Behavioral disturbance due to frontotemporal dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Problem Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

